Benutzer: Gast  Login
Titel:

Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.

Dokumenttyp:
Journal Article
Autor(en):
Dill, Veronika; Kauschinger, Johanna; Hauch, Richard T; Buschhorn, Lars; Odinius, Timo O; Müller-Thomas, Catharina; Mishra, Ritu; Kyncl, Michele C; Schmidt, Burkhard; Prodinger, Peter M; Hempel, Dirk; Bellos, Frauke; Höllein, Alexander; Kern, Wolfgang; Haferlach, Torsten; Slotta-Huspenina, Julia; Bassermann, Florian; Peschel, Christian; Götze, Katharina S; Waizenegger, Irene C; Höckendorf, Ulrike; Jost, Philipp J; Jilg, Stefanie
Abstract:
INTRODUCTION: Targeting the cell cycle machinery represents a rational therapeutic approach in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Despite substantial response rates, clinical use of the PLK inhibitor volasertib has been hampered by elevated side effects such as neutropenia and infections. OBJECTIVES: The primary objective was to analyse whether a reduced dose of volasertib was able to limit toxic effects on the healthy haematopoiesis while retaining its...     »
Zeitschriftentitel:
Eur J Haematol
Jahr:
2020
Band / Volume:
104
Heft / Issue:
2
Seitenangaben Beitrag:
125-137
Volltext / DOI:
doi:10.1111/ejh.13354
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/31758597
Print-ISSN:
0902-4441
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Allgemeine Pathologie und Pathologische Anatomie; Institut für Klinische Chemie und Pathobiochemie; Klinik und Poliklinik für Orthopädie und Sportorthopädie
 BibTeX